Sena Biswas MBA, Ph.D.

Venture Partner

Dr. Biswas has over three decades of experience as a biotechnology CEO, researcher, business development executive and venture capital investor. He has recently served as interim CEO at Mimetogen Pharmaceuticals and at Lumira portfolio companies KalGene Pharmaceuticals and OsteoQC. For over thirteen years he was a Managing Director at VIMAC Ventures, an early-stage life sciences venture capital firm in Boston. He was the first employee and President of Merrimack Pharmaceuticals which subsequently grew to a peak market capitalization of over $1.5 billion and successfully launched a cancer drug. Earlier in his career, Dr. Biswas was Director of Business Development at Rhone-Poulenc Rorer executing over 100 licensing and M&A transactions; Principal at TL Ventures, a $1.4 billion venture capital firm where he invested in the Series A rounds of Esperion, Adolor, ViroPharma, all of which became NASDAQ listed companies; and member of the Healthcare Investment Banking team at Bear, Stearns & Co. He holds a BA in Biology from Brandeis University, a PhD in Molecular and Cellular Biology from the University of Pennsylvania, an MBA from the Wharton School, and completed a postdoctoral fellowship in molecular immunology at Harvard Medical School.